EA202190603A1 - Полипептиды анти-her2 и способы их применения - Google Patents
Полипептиды анти-her2 и способы их примененияInfo
- Publication number
- EA202190603A1 EA202190603A1 EA202190603A EA202190603A EA202190603A1 EA 202190603 A1 EA202190603 A1 EA 202190603A1 EA 202190603 A EA202190603 A EA 202190603A EA 202190603 A EA202190603 A EA 202190603A EA 202190603 A1 EA202190603 A1 EA 202190603A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- her2
- antibody
- methods
- bbb
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721505P | 2018-08-22 | 2018-08-22 | |
| PCT/US2019/047728 WO2020041604A1 (en) | 2018-08-22 | 2019-08-22 | Anti-her2 polypeptides and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190603A1 true EA202190603A1 (ru) | 2021-07-14 |
Family
ID=67989062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190603A EA202190603A1 (ru) | 2018-08-22 | 2019-08-22 | Полипептиды анти-her2 и способы их применения |
Country Status (15)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CA3170338A1 (en) * | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| US20240392035A1 (en) * | 2021-08-25 | 2024-11-28 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| US20250066449A1 (en) * | 2021-12-31 | 2025-02-27 | Imnewrun, Inc. | Blood-brain barrier permeable fusion protein and uses thereof |
| KR20240067001A (ko) * | 2022-10-28 | 2024-05-16 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
| JP2025540336A (ja) * | 2022-12-08 | 2025-12-11 | アデル,インク | 抗タウ抗体及びペプチドを含む融合体とその用途 |
| CN120648654A (zh) * | 2024-03-13 | 2025-09-16 | 深圳太力生物技术有限责任公司 | 重组细胞的制备方法、重组细胞及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE423140T1 (de) * | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
| MX367126B (es) * | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
| WO2014089209A2 (en) * | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| WO2015191934A2 (en) * | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| JP7021955B2 (ja) * | 2015-06-24 | 2022-03-03 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法 |
| CN107446045A (zh) * | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
| RS63818B1 (sr) * | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| CA3053379A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| WO2019032955A1 (en) * | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
-
2019
- 2019-08-22 EP EP19769934.1A patent/EP3840781A1/en active Pending
- 2019-08-22 CN CN201980068845.5A patent/CN113286610A/zh active Pending
- 2019-08-22 WO PCT/US2019/047728 patent/WO2020041604A1/en not_active Ceased
- 2019-08-22 TW TW108130121A patent/TW202017947A/zh unknown
- 2019-08-22 AR ARP190102390A patent/AR115998A1/es unknown
- 2019-08-22 MX MX2021001976A patent/MX2021001976A/es unknown
- 2019-08-22 AU AU2019326545A patent/AU2019326545A1/en not_active Abandoned
- 2019-08-22 IL IL326298A patent/IL326298A/en unknown
- 2019-08-22 KR KR1020217008163A patent/KR20210074279A/ko not_active Ceased
- 2019-08-22 CA CA3141815A patent/CA3141815A1/en active Pending
- 2019-08-22 SG SG11202101436SA patent/SG11202101436SA/en unknown
- 2019-08-22 EA EA202190603A patent/EA202190603A1/ru unknown
- 2019-08-22 BR BR112021002953-2A patent/BR112021002953A2/pt unknown
- 2019-08-22 JP JP2021510094A patent/JP2021534220A/ja active Pending
-
2021
- 2021-02-16 IL IL280922A patent/IL280922B2/en unknown
- 2021-02-18 US US17/178,595 patent/US20220002436A1/en active Pending
-
2024
- 2024-07-25 JP JP2024119250A patent/JP7818042B2/ja active Active
-
2026
- 2026-01-07 AU AU2026200081A patent/AU2026200081A1/en active Pending
- 2026-02-06 JP JP2026018549A patent/JP2026086616A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL326298A (en) | 2026-04-01 |
| JP2021534220A (ja) | 2021-12-09 |
| KR20210074279A (ko) | 2021-06-21 |
| US20220002436A1 (en) | 2022-01-06 |
| IL280922B1 (en) | 2026-03-01 |
| CA3141815A1 (en) | 2020-02-27 |
| JP2026086616A (ja) | 2026-05-26 |
| CN113286610A (zh) | 2021-08-20 |
| JP7818042B2 (ja) | 2026-02-19 |
| IL280922B2 (en) | 2026-07-01 |
| AU2019326545A1 (en) | 2021-03-11 |
| AR115998A1 (es) | 2021-03-25 |
| IL280922A (en) | 2021-04-29 |
| TW202017947A (zh) | 2020-05-16 |
| EP3840781A1 (en) | 2021-06-30 |
| WO2020041604A1 (en) | 2020-02-27 |
| JP2024150674A (ja) | 2024-10-23 |
| BR112021002953A2 (pt) | 2021-05-11 |
| MX2021001976A (es) | 2021-06-08 |
| AU2026200081A1 (en) | 2026-01-29 |
| SG11202101436SA (en) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000652A (es) | Anticuerpos contra claudina 18 y metodos de tratamiento del cancer. | |
| PH12021550802A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| AR115998A1 (es) | Polipéptidos anti-her2 y métodos de uso de los mismos | |
| SA520420748B1 (ar) | أجسام مضادة للمركب الترابطي شبيه دلتا 3 /مجموعة من التمايز 3 ثنائية الخاصية | |
| MX2025012685A (es) | Anticuerpos para claudin6 y metodos para tratar el cancer | |
| PH12022550195A1 (en) | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| MX2023007520A (es) | Aglutinantes de albumina de suero mejorados. | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| MX2025010630A (es) | Aglutinantes de albumina serica mejorados | |
| MX2023005374A (es) | Aglutinantes de albumina serica mejorados. | |
| PH12021500051A1 (en) | Cd3 antigen binding fragments and compositions comprising same | |
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| MX2023001256A (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos. | |
| MX2024003355A (es) | Anticuerpos anti-cd3. | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| EA201992755A1 (ru) | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| ATE509032T1 (de) | Chimerizierte gm-csf antikörper | |
| EA201992467A1 (ru) | ГЕТЕРОДИМЕРИЗУЮЩИЕСЯ ДОМЕНЫ Ig | |
| MX2023011712A (es) | Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos. | |
| MX2021010877A (es) | Moleculas de union a cumulo de diferenciacion 3 (cd3). | |
| EA202092593A1 (ru) | Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| BR112022010824A2 (pt) | Anticorpo bifuncional contra pd-l1 e tgf¿ | |
| JOP20230223A1 (ar) | بولي ببتيد ربط gucy2c واستخداماته |